Financial Data and Key Metrics Changes - Total worldwide revenue in Q4 2025 was $22.6 million, a 5% decrease from $23.8 million in the same period last year, and a decrease of 7% on a constant currency basis [20] - Worldwide revenue for the full year 2025 was $90.5 million, an 8% increase over the prior year, and a 7% increase on a constant currency basis [20] - U.S. revenue in Q4 was $14.1 million, an 11% decrease from $15.9 million during the same period of the prior year [20] - International revenue in Q4 was $8.5 million, an 8% increase from $7.9 million during the same period last year [22] - Gross margin for Q4 was 77.6%, compared to 74% in the prior year [23] - Net loss for Q4 was $10.4 million or a loss of $0.25 per share, compared to a net loss of $13.2 million or a loss of $0.33 per share for the same period of the prior year [25] - Cash equivalents and marketable securities at the end of 2025 were $69.8 million, a decrease of $31.7 million from December 31, 2024 [26] Business Line Data and Key Metrics Changes - U.S. revenue for the full year 2025 was $57 million, a 1% increase over the prior year [21] - International revenue for the full year 2025 was $33.5 million, an increase of 23% over the prior year [22] - R&D expenses for Q4 were $4.6 million compared to $4 million in Q4 2024, reflecting increased clinical trial activity [24] - Sales, general, and administrative expenses for Q4 were $22.9 million compared to $27 million in Q4 2024 [24] Market Data and Key Metrics Changes - International growth was driven by continued strength in major European markets, offset by a lack of sales to the distributor in China [22] - The distributor in China is working through inventory from large orders placed in the first half of 2025, awaiting the renewal of the Chinese registration certificate expected in the second half of 2026 [22] Company Strategy and Development Direction - The company aims to re-accelerate U.S. sales growth, advance clinical initiatives, and align spending to deliver financial leverage towards profitability [7] - A focus on organizational alignment to optimize resources and decision-making in critical areas has been established [8] - The sales strategy is shifting to prioritize high-impact mandates and streamline the U.S. sales team's focus [10] - The AeriSeal program is a key focus for expanding the market, with the CONVERT II trial expected to complete enrollment in 2027 [15] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that the underperformance in U.S. revenue was largely due to internal operational challenges and has begun implementing strategies to address these issues [7][8] - The company expects to deliver full-year 2026 revenue in the range of $90 million-$92 million, with a return to year-over-year growth anticipated in the back half of the year [26] - Management is confident in the business fundamentals and is focused on demonstrating meaningful operating leverage and reducing cash burn starting in 2026 [19][28] Other Important Information - A cost restructuring initiative has reduced ongoing operating expenses by over 10% [18] - A $60 million credit facility has been secured, extending the maturity of existing debt to 2031 and providing access to additional capital [18] Q&A Session Summary Question: What percentage of the sales force turned over in Q4? - The turnover was across the entire year, with approximately half of the sales organization experiencing turnover [31] Question: How are sales incentives structured now? - The design of the compensation plan has been adjusted to ensure it is reasonable and well-understood, with a focus on effective quota allocation [34] Question: Why wouldn't growth return sooner with the new sales force in place? - The company is starting from a position of decline, and new reps require time to ramp up productivity [41] Question: What areas contributed to the 10% cost reduction? - Most savings came from G&A and marketing, while maintaining investments in key growth areas like sales and R&D [46] Question: How will AeriSeal and the CONVERT II trial be balanced with U.S. sales investments? - The company believes that the trial's execution will not significantly impact overall spending and will be aligned with commercial operations [52] Question: What is the status of sales in China? - Sales to China are expected to resume in the back half of 2026, with minimal contributions anticipated in the first half [78]

Pulmonx (NasdaqGS:LUNG) Q4 2025 Earnings call March 04, 2026 04:30 PM ET Company ParticipantsAnnie Tripodo - Equity Research AssociateDerrick Sung - COO and CFOGlen French - President and CEOLaine Morgan - Head of Investor RelationsSimran Kaur - Equity Research AssociateConference Call ParticipantsJason Bednar - Managing Director and Senior Research AnalystJon Young - Director and Equity Research AnalystNelson Cox - Equity Research AnalystOperatorThank you for standing by. Welcome to the Pulmonx Q4 2025 ear ...

Pulmonx (NasdaqGS:LUNG) Q4 2025 Earnings call March 04, 2026 04:30 PM ET Speaker2Thank you for standing by. Welcome to the Pulmonx fourth quarter 2025 earnings conference call. At this time, all participants are in listen only mode. After the speaker's presentation, we'll open up for questions. To ask a question during the session, you will need to press star 11 on your telephone. You'll hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be ...